Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks European, Middle Eastern Distribution Deals

NEW YORK (GenomeWeb) — Finnish diagnostics firm Mobidiag said today that it has signed three distribution deals for its Amplidiag and Novodiag lines of infectious disease and antibiotic resistance testing products in Europe and the Middle East.

According to Mobidiag, it has granted the exclusive distribution rights for the Amplidiag and Novodiag products to Helix2 in Greece and Interlab Interautomatika UAB in Latvia and Lithuania. It has also signed an exclusive distribution deal for the Novodiag line in Kuwait with Ibn Rushd Medical & Scientific Equipment.

The agreements have two-year terms. Additional details were not disclosed.

"We are delighted to have extended our commercial footprint into new international territories including our first agreement in the Middle East," Mobidiag CEO Tuomas Tenkanen said in a statement. "Mobidiag continues to see demand grow for the Amplidiag and Novodiag solutions and we are in discussions with several distribution partners in a range of international markets."

Earlier this month, Mobidiag announced the completion of a $11.3 million equity investment from Autobio Diagnostics, the proceeds of which will be used in part to continue its commercial expansion.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.